Page 43 - Pharma

Sequent Scientific opens analytical services centre in Bangalore

Built with a space of 10,000 square feet, the new Bangalore centre will enable company's access to a wider range of therapies including beta lactam and hormones

Merck Serono to invest Euro 65 mn for R&D facility expansion in Germany

The new building at Darmstadt, Germany, will unite different functions within R&D discovery technologies at Merck Serono

Dr Reddy's to market US-based PanTheryx's product DiaResQ in India

The agreement grants Dr Reddy's the exclusive right to market and distribute PanTheryx's nutritional intervention, DiaResQ, for infectious diarrhoea in India and Nepal

Bal Pharma enters into OTC segment with eye care product

Bal Pharma enters into OTC segment with eye care product This is the first among the series of OTC products that the company has lined up for launching in the market through its subsidiary, Lifezen He

Jubilant inks licensing pact with Cyclopharm for imaging agent in US

Jubilant DraxImage will have an exclusive license to market Technegas, an imaging agent primarily used in pulmonary embolism, in the US

Dr Reddy's inks commercialisation deal with Aussie firm Hatchtech for Xeglyze lotion

As part of the deal, Dr Reddy's will pay Hatchtech an upfront amount of $10 million, up to $ 50 million based on pre-commercialisation milestones

Solvay opens South-East Asia's largest sodium bicarbonate plant in Thailand

Built with an investment of Euro 20 million, the plant will have an annual production capacity of 100,000 tonnes and serve healthcare, food & other consumer goods markets in Asia

Lubrizol acquires contract drug developer Particle Sciences

The acquisitions broadens Lubrizol's LifeSciences application, pharmaceutical formulation and drug delivery capabilities

Evonik buys Dutch hydrogen peroxide producer PeroxyChem

The acquisition will enhance Evonik's hydrogen peroxide capacity in Europe

Bilcare Research plans capacity expansion in Germany

The expansion of Botzingen site, which delivers mono-films as well as coated and laminated films, will meet the growing demand for pharmaceutical packaging films in Europe

Valeant Pharma acquires Synergetics USA

The acquisition of Synergetics is expected to give a boost to the business of Bausch & Lomb, which Valeant had acquired in August 2013

Lupin launches anxiety drug duloxetine in US

The company claims to be the first company to launch generic duloxetine formulation in 40 mg dosage strength

Aurobindo Pharma receives US FDA nod for hypertension drug telmisartan

Telmisartan tablet has an estimated market size of $ 92 mllion for the twelve months ending July 2015, according to IMS

Sandoz launches first biosimilar drug Zarxio in US

Zarxio (also known as filgrastim-Sndz), a copy of Amgen's biotech drug Neupogen, is used to boost production of white blood cell in cancer patient

Glenmark's monoclonal antibody GBR 830 enters phase 2 trial

GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival

Amgen and Novartis to collaborate for Alzheimer's treatment

Global co-development agreement more rapidly advances Amgen's migraine programs, including AMG 334 in phase 3

Is global pharma industry investing enough in pain killer research?

Funding is difficult to come by for pain killer research since challenges of data collection for clinical trials is high as compared to any other therapeutic area

Cipla to acquire US-based Invagen and Exelan for $550 mn

This acquisition will give Cipla scale in the US generics market through a wide range of product portfolio in CNS, CVS, anti-infectives, diabetes as well as other value added generics

Novo Nordisk invests $75 mn in raw material warehouse in Denmark

The warehouse, to be located in Hillerod and having a capacity of around 17,000 pallets, is expected to be fully operational end 2017

Valeant inks license deal with AstraZeneca for psoriasis drug brodalumab

Valeant will make an up-front payment to AstraZeneca of $100 mn, as well as pre-launch milestones of up to $170 mn and further sales-related milestone payments of up to $175 mn following launch